Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Overview of attention for article published in PharmacoEconomics, September 2018

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 1 public wall post.

#HealthEconJA Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.